In Mauritania, almost 15% of the population is at high risk and 75% is at low risk of malaria. The annual reported number of malaria cases in 2018 was 175,841.
Malaria

Sustaining Essential Health Services During the COVID-19 Pandemic

The COVID-19 pandemic is putting an incredible strain on health systems across Africa. Health systems are required to maintain routine health services for other illnesses even as they handle the additional burden. In order to prevent widespread morbidity and mortality, it is of vital importance that we work to sustain the delivery of essential life-saving interventions during this difficult time including for Reproductive, Maternal, Newborn, Child and Adolescent health and malaria.

WHO underlines the critical importance of sustaining efforts to prevent, detect and treat malaria during the COVID-19 pandemic. It is of vital importance to ensure the continuity of malaria prevention and treatment services including distribution of insecticide-treated nets and indoor residual spraying, as well as chemoprevention for pregnant women and young children (intermittent preventive treatment in pregnancy and seasonal malaria chemoprevention). Any intervention must consider the importance of both lowering malaria-related mortality and ensuring the safety of communities and health workers given the ease of transmission of COVID-19.

For Mauritania, it will be of vital importance to ensure that the universal coverage campaign for long-lasting insecticidal nets (LLINs) scheduled for 2020 goes ahead, whilst taking into account physical distancing, in accordance with the recent guidance and recommendations from WHO and the RBM Partnership to End Malaria. Without this campaign, coupled with the need to also complete the seasonal malaria chemoprevention campaigns and sustain essential health services including malaria case management, there will be an increase in malaria cases and deaths. Under the worst-case scenario, in which all ITN campaigns are suspended and there is a 75% reduction in access to effective antimalarial medicines, WHO estimate that there could be a 27.3% increase in malaria cases, and a 79.4% increase in malaria deaths in Mauritania. This scenario would represent a complete reversal in the substantial progress in malaria mortality reductions seen over the last 2 decades.

Global Fund Update

The Global Fund has announced that Mauritania will receive US$19.6 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2021-2023. The Global Fund has determined the total allocation amount based on Mauritania’s disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and previous disbursements. For Mauritania this is calculated at US$12.5 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Mauritania is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

Progress

Mauritania has secured sufficient resources to meet the ACT and RDT requirements for 2020 and is implementing iCCM at scale. Mauritania has enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Scorecard. Mauritania has launched its Zero Malaria Starts with Me campaign.

Impact

The annual reported number of malaria cases in 2018 was 175,841.

Key Challenges

- The country has a less than 20% malaria case reporting rate by surveillance systems.
Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health including malaria.

### Previous Key Recommended Actions

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
<th>Progress</th>
<th>Comments - key activities/accomplishments since last quarterly report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vector Control</td>
<td>Report to WHO on the status of insecticide resistance, resistance monitoring and on the status of the national insecticide resistance monitoring and management plan</td>
<td>Q1 2017</td>
<td></td>
<td>No data have been collected recently due to lack of resources. The country plans to include a budget in the GF funding request for monitoring insecticide resistance</td>
</tr>
<tr>
<td>Impact</td>
<td>Investigate and address the reasons for the increase in estimated malaria mortality between 2010 and 2018</td>
<td>Q4 2019</td>
<td></td>
<td>Some of the factors contributing to the increase in deaths include, a decline in the GF malaria allocation, leading to gaps in coverage for key malaria control interventions, including LLINs in Nouakchott and SMC. Key actions have been put in place to address these constraints. This includes planning for the LLINs mass distribution in 2020 in high malaria burden districts and RDT distribution and training to enforce respect of the treatment guidelines. However, gaps still remain to achieve full coverage of targeted areas. Cases reduced in 2018. The LLIN campaign in 2020 is expected to lead to a further reduction in cases</td>
</tr>
<tr>
<td>Impact</td>
<td>Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic</td>
<td>Q4 2020</td>
<td></td>
<td>The NMCP has developed a strategy for implementing the LLIN mass campaign with COVID19 measures to the Ministry of Health’s COVID steering committee. The request is being reviewed and awaiting the Minister’s endorsement.</td>
</tr>
<tr>
<td>Address funding</td>
<td>Ensure the GF malaria funding application is submitted by Q2 2021 and ensure that resources are allocated to malaria control at a level that is sufficient to sustain the gains made in recent years</td>
<td>Q2 2021</td>
<td></td>
<td>Deliverable not yet due</td>
</tr>
</tbody>
</table>

**New Key Recommended Action**

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vector control</td>
<td>Work to address the falling LLIN coverage</td>
<td>Q4 2020</td>
</tr>
</tbody>
</table>

### RMNCAH and NTDs

**Progress**

Progress in addressing Neglected Tropical Diseases (NTDs) in Mauritania is measured using a composite index calculated from preventive chemotherapy coverage achieved for schistosomiasis, and trachoma. Preventive chemotherapy coverage in Mauritania is high for trachoma (100%), and good for schistosomiasis (77%). Overall, the NTD
preventive chemotherapy coverage index for Mauritania in 2018 is 88, which represents a large increase compared with the 2017 index value (3).

The country has achieved high coverage of the RMNCAH tracer indicator of vitamin A coverage.

**Previous Key Recommended Actions**

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
<th>Progress</th>
<th>Comments - key activities/accomplishments since last quarterly report</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMNCAH³ Impact</td>
<td>Ensure that essential RMNCAH services are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. Address any stock-outs of essential RMNCAH commodities</td>
<td>Q4 2020</td>
<td>Green</td>
<td>The country received technical support from partners to develop guidelines to ensure the continuity of nutrition services during the COVID-19 pandemic. Partners also supported the country to sustain health services including immunization, reproductive health services, and antenatal care) including with the development of adapted training tools, provision of equipment, and delivery of cold chain equipment.</td>
</tr>
</tbody>
</table>

Mauritania has responded positively to the RMNCAH recommended action addressing low coverage of ARTs in children under 14 years of age and continues to track progress as this action is implemented.

**Key**

- Action achieved
- Some progress
- No progress
- Deliverable not yet due

¹ RMNCAH metrics, recommended actions and response tracked through WHO